Lord, Abbett & Co’s Moderna MRNA Stock Holding History

Lord, Abbett & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-40,928	Closed	-$2.9M	–	686
2020 Q3	$2.9M	Buy	+40,928	New	+$2.85M	0.01%	595

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lord, Abbett & Co's MRNA Position: Q4 2020 in Review

Lord, Abbett & Co sold out of Moderna (MRNA) in Q4 2020, closing a stake of 40,928 shares — an estimated $2.9M sold.

Lord, Abbett & Co first reported a position in MRNA in Q3 2020 and held it in 1 quarter. The position peaked at $2.9M in Q3 2020. 717 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

Lord, Abbett & Co reported no remaining Moderna position as of Q4 2020 after selling out during the quarter.
Lord, Abbett & Co sold 40,928 Moderna shares in Q4 2020, an estimated $2.9M.
Lord, Abbett & Co first reported a position in Moderna in Q3 2020 and held it in 1 quarter.
Lord, Abbett & Co's Moderna position peaked at $2.9M in Q3 2020.
717 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on Lord, Abbett & Co's 13F filing for Q4 2020, filed 9 Feb 2021.